Pharm
Diethylstilbestrol Exposure
search
Diethylstilbestrol Exposure
, Diethylstilbestrol, DES, DES Exposure
See Also
Teratogen
Background
Diethylstilbestrol (DES) is an oral synthetic nonsteroidal
Estrogen
Diethylstilbestrol (DES) was prescribed in pregnancy
Was used to improve pregnancy outcomes
Later studies did not support any benefit for DES
Used in U.S. 1938 to 1971
Used in Europe until 1980's
Diethylstilbestrol (DES) is now only indicated in men with advanced
Prostate Cancer
Associated Conditions
DES Exposure (highly correlated)
Associated with in utero exposure to DES
Highest risk were patients exposed in first trimester
Carcinoma
Vaginal clear cell adenocarcinoma
Peak onset age 17 to 22 years
Possibly second peak at post-
Menopause
Breast Cancer
(same risk as
Hormone Replacement
)
Gynecologic tract abnormalities
T-shaped
Uterus
Adenosis
Cervical abnormalities (e.g. pseudopolyp)
Risks in men exposed in utero to DES
Undescended Testes
Small
Testes
Possible
Prostate Cancer
risk
Possible
Testicular Cancer
risk
Management
Surveillance of women with in utero DES Exposure history
Colposcopy
at first
Pap Smear
Repeat annually (at minimum) for abnormalities
Routine
Colposcopy
not needed if normal
Annual
Pap Smear
, four quadrants and pelvic exam
Sample cells with brush from four vaginal quadrants
Routine
Pap Smear
Bimanual exam
Pregnancy management
Discuss higher risk of
Miscarriage
and poor outcomes
Refer to obstetrics if pregnant
References
Giusti (1995) Ann Intern Med 122:778-88 [PubMed]
Schrager (2004) Am Fam Physician 69:2395-402 [PubMed]
Type your search phrase here